I.V. Bulycheva

И.В. Булычева

11 articles 2010–2022

2022

Clinical and laboratory significance of endostatin in blood serum of adolescents with bone sarcomas Technologies of Living Systems, No. 4, 2022 pp. 24-32

2020

Survival of Ewing sarcoma and chondrosarcoma patients in relation to matrix metalloproteinases and their tissue inhibitors levels in blood serum Achievements of Modern Radioelectronics, No. 1, 2020 pp. 15-22

2019

Comparative analysis of tissue inhibitors of matrix metalloproteinases in malignant and borderline bone tumors Technologies of Living Systems, No. 4, 2019 pp. 16-21

2014

Bone lesions in children and adolescence Вопросы биологической, медицинской и фармацевтической химии, No. 8, 2014 pp. 66-70

2013

Genetic studies of bone tumors Technologies of Living Systems, No. 2, 2013 pp. 5-17

2012

Molecular biologic markers expression in chondrosarcomas, its association with clinic-morphologic characteristics and prognosis Technologies of Living Systems, No. 9, 2012 pp. 68-75
Ewing family tumors (Ewing sarcoma/primitive neuroectodermal tumor ES/PNET). Сlinical and morphologic research Technologies of Living Systems, No. 9, 2012 pp. 38-42
Insulin-like growth factors 1 and 2, and insuline-like growth factor binding proteins 1 and 3 in bone tumors Technologies of Living Systems, No. 9, 2012 pp. 33-37
Notochordal tumors (chordoma). Differential diagnosis. Immunohistochemical markers Technologies of Living Systems, No. 3, 2012 pp. 24-28

2011

Molecular biological markers expression in bone osteosarcomas Вопросы биологической, медицинской и фармацевтической химии, No. 2, 2011 pp. 55-62

2010

Matix metalloproteinases 1, 2, 9 in cartilaginous bone tumors Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2010 pp. 59-64